ROS Cancer Research Results

ROS, Reactive Oxygen Species: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy
ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination

Item ROS NRF2 Condition Mechanism Class Remarks
ROS">Piperlongumine +++ [D][T] ROS-dominant
ROS">Shikonin +++↓/±[D][T]ROS-dominant
ROS">Vitamin K3 (menadione) +++[D]ROS-dominant
ROS">Copper (ionic / nano) +++[Fe][F]ROS-dominant
ROS">Sodium Selenite +++[D]ROS-dominant
ROS">Juglone +++[D]ROS-dominant
ROS">Auranofin +++[D]ROS-dominant
ROS">Photodynamic Therapy (PDT) +++0[L][O₂]ROS-dominant
ROS">Radiotherapy / Radiation +++0[O₂]ROS-dominant
ROS">Doxorubicin +++[D]ROS-dominant
ROS">Cisplatin ++[D][T]ROS-dominant
ROS">Salinomycin ++[D][T]ROS-dominant
ROS">Artemisinin / DHA ++[Fe][T]ROS-dominant
ROS">Sulfasalazine ++[C][T]ROS-dominant
ROS">FMD / fasting ++[M][C][O₂]ROS-dominant
ROS">Vitamin C (pharmacologic) ++[Fe][D]ROS-dominant
ROS">Silver nanoparticles ++±[F][D]ROS-dominant
ROS">Gambogic acid ++[D][T]ROS-dominant
ROS">Parthenolide ++[D][T]ROS-dominant
ROS">Plumbagin ++[D]ROS-dominant
ROS">Allicin ++[D]ROS-dominant
ROS">Ashwagandha (Withaferin A) ++[D][T]ROS-dominant
ROS">Berberine ++[D][M]ROS-dominant
ROS">PEITC ++[D][C]ROS-dominant
ROS">Methionine restriction +[M][C][T]ROS-secondary
ROS">DCA +±[M][T]ROS-secondary
ROS">Capsaicin +±[D][T]ROS-secondary
ROS">Galloflavin +0[D]ROS-secondary
ROS">Piperine +±[D][F]ROS-secondary
ROS">Propyl gallate +[D]ROS-secondary
ROS">Scoulerine +?[D][T]ROS-secondary
ROS">Thymoquinone ±±[D][T]Dual redox
ROS">Emodin ±±[D][T]Dual redox
ROS">Alpha-lipoic acid (ALA) ±[D][M]NRF2-dominant
ROS">Curcumin ±↑/↓[D][F]NRF2-dominant
ROS">EGCG ±↑/↓[D][O₂]NRF2-dominant
ROS">Quercetin ±↑/↓[D][Fe]NRF2-dominant
ROS">Resveratrol ±[D][M]NRF2-dominant
ROS">Sulforaphane ±↑↑[D]NRF2-dominant
ROS">Lycopene 0Antioxidant
ROS">Rosmarinic acid 0Antioxidant
ROS">Citrate 00Neutral


GC, Gastric Adenocarcinoma: Click to Expand ⟱
Stomach/Gastric Cancer

Scientific Papers found: Click to Expand⟱
5356- AL,    Therapeutic role of allicin in gastrointestinal cancers: mechanisms and safety aspects
- Review, GC, NA
Apoptosis↑, TumCP↓, MAPK↓, PI3K↓, Akt↓, NF-kB↓, AntiCan↑, ChemoSen↑, TumCCA↑, Apoptosis↑, BioAv↑, selectivity↑, TGF-β↓, ROS↑, DNAdam↑, p‑P53↑, P21↑, cycD1/CCND1↓, cycE/CCNE↓, CDK4↓, CDK6↓, MMP↓, NF-kB↑, BAX↑, Bcl-2↓, ER Stress↑, Casp↑, AIF↑, Fas↑, Casp8↑, Cyt‑c↑, cl‑PARP↑, Ca+2↑, *NRF2↑, *chemoP↑, *GutMicro↑, CycB/CCNB1↑, H2S↑, HIF-1↓, RadioS↑,
2655- AL,    Allicin and Digestive System Cancers: From Chemical Structure to Its Therapeutic Opportunities
- Review, GC, NA
TGF-β↓, cycD1/CCND1↓, cycE/CCNE↓, CDK1↓, DNAdam↑, ROS↑, BAX↑, JNK↑, MMP↓, p38↑, MAPK↑, Fas↑, Cyt‑c↑, Casp8↑, PARP↑, Casp3↑, Casp9↑, Ca+2↑, ER Stress↑, P21↑, CDK2↓, CDK6↑, TumCCA↑, CDK4↓,
239- AL,    Allicin induces apoptosis in gastric cancer cells through activation of both extrinsic and intrinsic pathways
- in-vitro, GC, SGC-7901
Apoptosis↑, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, BAX↑, Fas↑, tumCV↓, DNAdam↑, ROS↑, Telomerase↓,
2631- Api,    Apigenin Induces Autophagy and Cell Death by Targeting EZH2 under Hypoxia Conditions in Gastric Cancer Cells
- in-vivo, GC, NA - in-vitro, GC, AGS
ER Stress↑, Hif1a↓, EZH2↓, HDAC↓, TumAuto↑, p‑mTOR↓, AMPKα↑, GRP78/BiP↑, ROS↑, MMP↓, Ca+2↑, ATF4↑, CHOP↑,
5501- Ba,    Therapeutic effects and mechanisms of action of Baicalein on stomach cancer: a comprehensive systematic literature review
- Review, GC, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, BAX↑, TumAuto↑, ROS↑, NRF2↝, PI3K↓, Akt↓, NF-kB↓, TGF-β↓, SMAD4↓, GPx4↓, MMP↓, *HO-1↑, *GSTs↑, *antiOx↑, *AntiTum↑, *NRF2↑, ChemoSen↑, Akt↓, mTOR↓, FAK↓, Ki-67↓,
2295- Ba,  5-FU,    Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway
- in-vitro, GC, AGS
ChemoSen↑, HK2↓, LDHA↓, PDK1↓, Akt↓, PTEN↑, Hif1a↓, Glycolysis↓, ROS↑, CHOP↑,
1395- BBR,    Analysis of the mechanism of berberine against stomach carcinoma based on network pharmacology and experimental validation
- in-vitro, GC, NA
Apoptosis↑, ROS↑, MMP↓, ATP↓, AMPK↑, TP53↑, p‑MAPK↓, p‑ERK↓,
1394- BBR,  DL,    Synergistic Inhibitory Effect of Berberine and d-Limonene on Human Gastric Carcinoma Cell Line MGC803
- in-vitro, GC, MGC803
eff↑, ROS↑, MMP↓, Casp3↑, Bcl-2↓, TumCCA↑,
1392- BBR,    Based on network pharmacology and experimental validation, berberine can inhibit the progression of gastric cancer by modulating oxidative stress
- in-vitro, GC, AGS - in-vitro, GC, MKN45
TumCG↓, TumCMig↓, ROS↑, MDA↑, SOD↓, NRF2↓, HO-1↓, Hif1a↓, EMT↓, Snail↓, Vim↓,
1396- BBR,    Berberine induced down-regulation of matrix metalloproteinase-1, -2 and -9 in human gastric cancer cells (SNU-5) in vitro
- in-vitro, GC, SNU1041 - in-vitro, GC, SNU5
tumCV↓, ROS↑, MMP1↓, MMP2↓, MMP9↓, MMP7∅,
5843- CAP,    The Effects of Capsaicin on Gastrointestinal Cancers
- Review, GC, NA
*BioAv↑, ROS↑, Apoptosis↑, Glycolysis↓, HK2↓, MMP9↓, AMPK↑, TumCP↓, Casp3↑, Bcl-2↓, P53↑, BAX↑,
939- Catechins,  5-FU,    Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil
- vitro+vivo, GC, SNU620
lactateProd↓, ROS↑, tumCV↓, LDHA↓, mt-ROS↑, proApCas↑,
1593- Citrate,    Citrate Induces Apoptotic Cell Death: A Promising Way to Treat Gastric Carcinoma?
- in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901
PFK↓, Glycolysis↓, tumCV↓, cl‑Casp3↑, cl‑PARP↑, Apoptosis↑, ATP↓, ChemoSen↑, Mcl-1↓, glucoNG↑, FBPase↑, OXPHOS↓, TCA↓, β-oxidation↓, HK2↓, PDH↓, ROS↑,
410- CUR,    Nrf2 depletion enhanced curcumin therapy effect in gastric cancer by inducing the excessive accumulation of ROS
- vitro+vivo, GC, AGS - vitro+vivo, GC, HGC27
ROS↑, NRF2↑,
454- CUR,    Curcumin-Induced DNA Demethylation in Human Gastric Cancer Cells Is Mediated by the DNA-Damage Response Pathway
- in-vitro, GC, MGC803
TumCMig↓, TumCP↓, ROS↑, mtDam↑, DNAdam↑, Apoptosis↑, ATR↑, P21↑, p‑P53↑, GADD45A↑, p‑γH2AX↑,
1607- EA,    Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions
- Review, GC, NA
STAT3↓, TumCP↓, Apoptosis↑, NF-kB↓, EMT↓, RadioS↑, antiOx↑, COX1↓, COX2↓, cMyc↓, Snail↓, Twist↓, MMP2↓, P90RSK↓, CDK8↓, PI3K↓, Akt↓, TumCCA↑, Casp8↑, PCNA↓, TGF-β↓, Shh↓, NOTCH↓, IL6↓, ALAT↓, ALP↓, AST↓, VEGF↓, P21↑, *toxicity∅, *Inflam↓, *cardioP↑, *neuroP↑, *hepatoP↑, ROS↑, *NRF2↓, *GSH↑,
2842- FIS,    Fisetin inhibits cellular proliferation and induces mitochondria-dependent apoptosis in human gastric cancer cells
- in-vitro, GC, AGS
TumCCA↑, CDK2↓, P53↑, selectivity↑, MMP↓, DNAdam↑, cl‑PARP↑, mt-ROS↑, eff↓, survivin↓,
1927- JG,    Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway
- in-vitro, GC, SGC-7901
Apoptosis↑, ROS↑, Bcl-2↓, BAX↑, MMP↓, Cyt‑c↑, Casp3?, Bax:Bcl2↑,
2913- LT,    Luteolin induces apoptosis by impairing mitochondrial function and targeting the intrinsic apoptosis pathway in gastric cancer cells
- in-vitro, GC, HGC27 - in-vitro, BC, MCF-7 - in-vitro, GC, MKN45
TumCP↓, MMP↓, Apoptosis↑, ROS↑, SOD↓, ATP↓, Bax:Bcl2↑, TumCCA↑,
1254- PI,  VitC,    Piperlongumine combined with vitamin C as a new adjuvant therapy against gastric cancer regulates the ROS–STAT3 pathway
- in-vivo, GC, NA
STAT3⇅, eff↑, ROS↑, Apoptosis↑,
1947- PL,    Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer
- in-vitro, GC, SGC-7901 - in-vitro, GC, NA
TrxR1↓, ROS↑, ER Stress↑, mtDam↑, selectivity↑, NO↑, TumCCA↑, mt-ROS↑, Casp9↑, Bcl-2↓, Bcl-xL↓, cl‑PARP↑, eff↓, lipid-P↑,
2968- PL,  Chit,    Preparation of piperlongumine-loaded chitosan nanoparticles for safe and efficient cancer therapy
- in-vitro, GC, AGS
eff↑, Dose↝, ROS↑, BioAv↑,
5026- QC,    Quercetin induces ferroptosis in gastric cancer cells by targeting SLC1A5 and regulating the p-Camk2/p-DRP1 and NRF2/GPX4 Axes
- in-vitro, GC, NA
SLC1A5↓, ROS↑, Iron↓, NRF2↓, GPx4↓, Ferroptosis↑,
1471- SFN,    ROS-mediated activation of AMPK plays a critical role in sulforaphane-induced apoptosis and mitotic arrest in AGS human gastric cancer cells
- in-vitro, GC, AGS
TumCP↓, Apoptosis↑, TumCCA↑, CycB/CCNB1↑, P21↑, p‑H3↑, p‑AMPK↑, eff↓, MMP↓, Cyt‑c↑, ROS↑, eff↓,
2199- SK,    Induction of Ferroptosis by Shikonin in Gastric Cancer via the DLEU1/mTOR/GPX4 Axis
- in-vitro, GC, NA
ROS↑, lipid-P↑, Iron↑, MDA↑, GPx4↓, Ferritin↓, DLEU1↓, mTOR↓, Ferroptosis↑,
2227- SK,    Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species
- in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901 - in-vitro, Nor, GES-1
selectivity↑, TumCP↓, TumCD↑, ROS↑, MMP↓, Casp↑, Cyt‑c↑, Endon↑, AIF↑, eff↓, ChemoSen↑, TumCCA↑, GSH/GSSG↓, lipid-P↑,
1280- SK,    Shikonin Induces Apoptotic Cell Death via Regulation of p53 and Nrf2 in AGS Human Stomach Carcinoma Cells
- in-vitro, GC, AGS
ROS↑, Casp3↑, P53↑, NRF2↓,
5080- SSE,    Sodium Selenite Regulates the Proliferation and Apoptosis of Gastric Cancer Cells by Suppressing the Expression of LncRNA HOXB-AS1
- in-vitro, GC, HGC27 - in-vitro, GC, NCI-N87
AntiTum↑, HOXB-AS1↓, TumCP↓, TumCI↓, Apoptosis↑, BAD↓, Bcl-2↓, cl‑Casp3↑, MMP2↓, E-cadherin↑, N-cadherin↓, ROS↑, NF-kB↓,

Showing Research Papers: 1 to 28 of 28

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 28

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

antiOx↑, 1,   Ferroptosis↑, 2,   GPx4↓, 3,   GSH/GSSG↓, 1,   HO-1↓, 1,   Iron↓, 1,   Iron↑, 1,   lipid-P↑, 3,   MDA↑, 2,   NRF2↓, 3,   NRF2↑, 1,   NRF2↝, 1,   OXPHOS↓, 1,   ROS↑, 27,   mt-ROS↑, 3,   SOD↓, 2,   TrxR1↓, 1,  

Metal & Cofactor Biology

Ferritin↓, 1,  

Mitochondria & Bioenergetics

AIF↑, 2,   ATP↓, 3,   MMP↓, 11,   mtDam↑, 2,  

Core Metabolism/Glycolysis

ALAT↓, 1,   AMPK↑, 2,   p‑AMPK↑, 1,   cMyc↓, 1,   FBPase↑, 1,   glucoNG↑, 1,   Glycolysis↓, 3,   H2S↑, 1,   HK2↓, 3,   lactateProd↓, 1,   LDHA↓, 2,   PDH↓, 1,   PDK1↓, 1,   PFK↓, 1,   SLC1A5↓, 1,   TCA↓, 1,   β-oxidation↓, 1,  

Cell Death

Akt↓, 5,   Apoptosis↑, 14,   BAD↓, 1,   BAX↑, 6,   Bax:Bcl2↑, 2,   Bcl-2↓, 6,   Bcl-xL↓, 1,   Casp↑, 2,   Casp3?, 1,   Casp3↑, 5,   cl‑Casp3↑, 2,   Casp8↑, 4,   Casp9↑, 3,   Cyt‑c↑, 6,   Endon↑, 1,   Fas↑, 3,   Ferroptosis↑, 2,   JNK↑, 1,   MAPK↓, 1,   MAPK↑, 1,   p‑MAPK↓, 1,   Mcl-1↓, 1,   p38↑, 1,   proApCas↑, 1,   survivin↓, 1,   Telomerase↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction

AMPKα↑, 1,  

Transcription & Epigenetics

DLEU1↓, 1,   EZH2↓, 1,   p‑H3↑, 1,   tumCV↓, 4,  

Protein Folding & ER Stress

CHOP↑, 2,   ER Stress↑, 4,   GRP78/BiP↑, 1,  

Autophagy & Lysosomes

TumAuto↑, 2,  

DNA Damage & Repair

ATR↑, 1,   DNAdam↑, 5,   GADD45A↑, 1,   P53↑, 3,   p‑P53↑, 2,   PARP↑, 1,   cl‑PARP↑, 4,   PCNA↓, 1,   TP53↑, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence

CDK1↓, 1,   CDK2↓, 2,   CDK4↓, 2,   CycB/CCNB1↑, 2,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 2,   P21↑, 5,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State

CDK8↓, 1,   EMT↓, 2,   p‑ERK↓, 1,   HDAC↓, 1,   HOXB-AS1↓, 1,   mTOR↓, 2,   p‑mTOR↓, 1,   NOTCH↓, 1,   P90RSK↓, 1,   PI3K↓, 3,   PTEN↑, 1,   Shh↓, 1,   STAT3↓, 1,   STAT3⇅, 1,   TumCG↓, 1,  

Migration

Ca+2↑, 3,   E-cadherin↑, 1,   FAK↓, 1,   Ki-67↓, 1,   MMP1↓, 1,   MMP2↓, 3,   MMP7∅, 1,   MMP9↓, 2,   N-cadherin↓, 1,   SMAD4↓, 1,   Snail↓, 2,   TGF-β↓, 4,   TumCI↓, 1,   TumCMig↓, 2,   TumCP↓, 9,   TumMeta↓, 1,   Twist↓, 1,   Vim↓, 1,  

Angiogenesis & Vasculature

ATF4↑, 1,   HIF-1↓, 1,   Hif1a↓, 3,   NO↑, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling

COX1↓, 1,   COX2↓, 1,   IL6↓, 1,   NF-kB↓, 4,   NF-kB↑, 1,  

Hormonal & Nuclear Receptors

CDK6↓, 1,   CDK6↑, 1,  

Drug Metabolism & Resistance

BioAv↑, 2,   ChemoSen↑, 5,   Dose↝, 1,   eff↓, 5,   eff↑, 3,   RadioS↑, 2,   selectivity↑, 4,  

Clinical Biomarkers

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   EZH2↓, 1,   Ferritin↓, 1,   IL6↓, 1,   Ki-67↓, 1,   TP53↑, 1,  

Functional Outcomes

AntiCan↑, 2,   AntiTum↑, 1,  
Total Targets: 155

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 1,   GSH↑, 1,   GSTs↑, 1,   HO-1↑, 1,   NRF2↓, 1,   NRF2↑, 2,  

Immune & Inflammatory Signaling

Inflam↓, 1,  

Drug Metabolism & Resistance

BioAv↑, 1,  

Clinical Biomarkers

GutMicro↑, 1,  

Functional Outcomes

AntiTum↑, 1,   cardioP↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   toxicity∅, 1,  
Total Targets: 15

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species
4 Berberine
3 Allicin (mainly Garlic)
3 Shikonin
2 Baicalein
2 5-fluorouracil
2 Curcumin
2 Piperlongumine
1 Apigenin (mainly Parsley)
1 D-limonene
1 Capsaicin
1 Catechins
1 Citric Acid
1 Ellagic acid
1 Fisetin
1 Juglone
1 Luteolin
1 Piperine
1 Vitamin C (Ascorbic Acid)
1 chitosan
1 Quercetin
1 Sulforaphane (mainly Broccoli)
1 Selenite (Sodium)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:28  Cells:%  prod#:%  Target#:275  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page